<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649762</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0202</org_study_id>
    <nct_id>NCT04649762</nct_id>
  </id_info>
  <brief_title>the Activating Consciousness Technique (Hypnosis) in General Practice</brief_title>
  <acronym>MG HYPNOSIS</acronym>
  <official_title>Evaluation of the Activating Consciousness Technique (Hypnosis) in Anxiety in a General Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anxiety is an emotion considered unpleasant but resulting from a normal phenomenon. It&#xD;
      corresponds to an adaptive response to events, to stress and helps to ensure our survival.&#xD;
&#xD;
      On the other hand, it becomes embarrassing when it becomes uncontrollable. It can even lead&#xD;
      to interfere with activities of daily living. Thus, we can speak of anxiety disorder.&#xD;
&#xD;
      Anxiety disorders are among the most prevalent psychiatric disorders. They are often&#xD;
      associated with other comorbidities such as depression, which makes them more difficult to&#xD;
      treat and diagnose.&#xD;
&#xD;
      Different treatments are offered to best treat the patient with anxiety : drug treatment&#xD;
      (antidepressants, anxiolytics) ; non-drug (psychotherapy, meditation, cognitive behavioral&#xD;
      therapies).&#xD;
&#xD;
      The emergence of hypnosis in medical practice in recent years seems to be a technique that&#xD;
      can bring benefits to the patient.&#xD;
&#xD;
      A review of clinical studies does not seem to find a benefit to hypnosis in anxiety&#xD;
      disorders. In contrast, a study in children with school phobia showed the effectiveness of&#xD;
      hypnosis. The limits addressed by this review seem to relate to the number of people included&#xD;
      in the studies. Contrariwise, it has been pointed out that hypnosis can have a beneficial&#xD;
      effect in the long term.&#xD;
&#xD;
      Thus, it seems interesting to deepen this technique in the practice of a general practitioner&#xD;
      exercising the activating consciousness technique in anxiety.&#xD;
&#xD;
      The study will be composed of patients presenting with anxiety and consulting their general&#xD;
      practitioner, with: Group 1, patients consulting a doctor not practicing hypnosis Versus&#xD;
      Group 2, patients consulting a doctor practicing hypnosis.&#xD;
&#xD;
      During the first consultation and the following 2 consultations scheduled by the general&#xD;
      practitioner (spaced 15 days apart), the following data are noted, in addition to the&#xD;
      monitoring usually performed by the doctor:&#xD;
&#xD;
        1. COVI scale&#xD;
&#xD;
        2. Comfort scale 0 to 10&#xD;
&#xD;
        3. Management: drugs, TAC, others&#xD;
&#xD;
        4. Quality of life survey SF36 Patients will be called back at 6 months to reassess quality&#xD;
           of life (self-administered survey SF 36) The primary endpoint is to evaluated the change&#xD;
           of anxiety from inclusion (J0) to 6 months using COVI scale in the two different groups.&#xD;
&#xD;
      For secondary endpoints, the consumption of drug medicine will be quantified and the quality&#xD;
      of life will be measured using Quality of life survey SF36.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the score of anxiety from inclusion (J0) to 6 months evaluated byvia COVI scale</measure>
    <time_frame>6 months</time_frame>
    <description>COVI scale (questionnaire completed by patients) is a scale that permits to evaluate the clinical anxiety. The range is 0-100. The higher the score, the more the anxiety. The clinical cut-off score is 30.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Group 1 includes patients with anxiety consulting a doctor not practicing hypnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAC</arm_group_label>
    <description>Group 2 includes patients with anxiety consulting a doctor practicing hypnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>activating consciousness technique (hypnosis)</intervention_name>
    <description>activating consciousness technique (hypnosis)</description>
    <arm_group_label>TAC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with anxiety according to DSM V-C criteria: 3 of 6 symptoms&#xD;
&#xD;
          -  Agitation or sensation of being overflown or exhausted&#xD;
&#xD;
          -  Fatigability&#xD;
&#xD;
          -  Difficulty concentrating or memory lapses&#xD;
&#xD;
          -  Irritability&#xD;
&#xD;
          -  Muscle tension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female over 18&#xD;
&#xD;
          -  Anxiety patient&#xD;
&#xD;
          -  Patient who can return for consultation regularly and can be reached by phone&#xD;
&#xD;
          -  Patient Not Opposing Participation In Study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Follow-up deemed impossible by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lidwine LAURENT</last_name>
    <phone>0626550636</phone>
    <phone_ext>+33</phone_ext>
    <email>lidwine.laurent@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr Stéphane FOLACHER</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>01000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane FOLACHER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane FOLACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Céline HUMBERT</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline HUMBERT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céline HUMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Matthieu DEMOURGUES</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu DEMOURGUES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthieu DEMOURGUES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Aurélien BARADEL</name>
      <address>
        <city>Saint-Martin-du-Fresne</city>
        <zip>01430</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auurélien BARADEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélien BARADEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Christian SAINT-CYR</name>
      <address>
        <city>Saint-Étienne-du-Bois</city>
        <zip>01370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian SAINT-CYR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian SAINT-CYR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Maud BINARD</name>
      <address>
        <city>Villereversure</city>
        <zip>01250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud BINARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maud BINARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pelissolo A. [Hypnosis for anxiety and phobic disorders: A review of clinical studies]. Presse Med. 2016 Mar;45(3):284-90. doi: 10.1016/j.lpm.2015.12.002. Epub 2016 Mar 2. Review. French.</citation>
    <PMID>26944812</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypnosis</keyword>
  <keyword>anxiety</keyword>
  <keyword>general practice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

